

LITHUANIA

Recent and planned developments in pharmaceutical policies 2018

Special topic: national incentives and derogatory procedures for orphan medicines

CHANGES IN PRICING

1
July 2018

Price for generics and biosimilars:
First generic enters market → 30% reduction
First biosimilar enters market → 20% reduction

1
July 2018

Wholesales and pharmacy mark-up changes

WHOLESALE MARK UP SCHEME	PHARMACY MARK UP SCHEME
Manufacturer price in EUR / Maximum wholesalers mark up of manufacturers price in EUR	Pharmacy purchasing price in EUR / Maximum pharmacy mark up of pharmacy purchasing price in EUR
<ul style="list-style-type: none"> • up to 49,99 EUR / 0,51 EUR • 50 to 263,29 EUR / 2,45 EUR • 263,3 EUR and more / 5,79 EUR 	<ul style="list-style-type: none"> • up to 47,46 EUR / 1,00 EUR • 47,46 to 144,8 EUR / 5,10 EUR • 144,81 EUR and more / 14,48 EUR

CHANGES IN REIMBURSEMENT

1
July 2018

Fixed patient co-payment if medicine is reimbursed at 100 % level

- if medicinal products retail price is up to 20 Eur – patient co-payment 20% reimbursed (basic) price;
- medicinal products retail price more than 20 Eur – patient co-payment 4,11 Eur

16
July 2018

Changes in reimbursement levels

- all medicinal products that are reimbursed 80 and 90 % basic price, reimbursement level increase till 100 % ;
- all medicinal products that are used for cardiovascular diseases (ATC classification – C) and that are reimbursed 80 % basic price, reimbursement level increase till 90 %;

OTHERS CHANGES

1
July 2018

Change of reference countries in external price referencing

- Reference countries are all ES counties that prices are available in database (before: reference countries were 8 countries: Latvia, Estonia, Poland, Czech Republic, Hungary, Slovakia, Romania, Bulgaria);
- The reimbursement price is calculated according average of the 3 lowest prices in EU countries

SPECIAL TOPIC: National Incentives and Derogatory Procedures for Orphan Medicines

Market access prior to marketing authorisation	Availability and assessment of orphans	Pricing and funding	Place of treatment
<ul style="list-style-type: none"> • Compassionate-use programs are allowed, but not encouraged, since later on they create more difficulties when making decision to reimburse or not the medicine for orphan diseases 	<ul style="list-style-type: none"> • The products which are authorised via central authorisation in EU are available, sometimes the physicians who are dealing with patients with rare diseases make the first connections with companies • The dossiers are not assessed via typical HTA process in LT, they are assessed separately and no scores are applied 	<ul style="list-style-type: none"> • If the price of treatment of one patient is less than 30 000 eur, the Commission compares prices of the medicinal product with prices in other EU countries, • If the price of annual treatment exceeds 30 000 but is not higher 100 000 eur, the Commission prepares a letter to producer with the offer to share expenses. • If the price of one patient treatment is higher than 100 000 eur, the negotiation is performed by the Negotiation Committee • There is the fund for rare diseases. They are funded from the separate line in NHIF budget. • Patients can be reimbursed on name patient base. 	<ul style="list-style-type: none"> • There is one Centre of Expertise for rare diseases and two university hospitals, which are mostly involved in taking care of patients with rare diseases

